Surufatinib achieves radiosensitivity in cholangiocarcinoma by suppressing GINS4 expression to induce Ca2+/cAMP signaling activation

doi:10.3748/wjg.121690

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 32, Issue 42

This Article

(3)

(0)

(27)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Basic Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Gastroenterol. Nov 14, 2026; 32(42): 121690
Published online Nov 14, 2026. doi: 10.3748/wjg.121690

Table 1 The relative parameters of cell survival curves after irradiation

Parameter/cell lines	NOZ		TFK-1
Parameter/cell lines	Control	Surufatinib	Control	Surufatinib
D₀	2.055	1.926	1.772	1.573
Dq	2.054	0.683	2.202	0.760
N	2.717	1.426	3.464	1.621
SF₂	72.47%	46.37%	74.16%	41.36%
SER	/	3.01	/	2.90

D₀: Lethal dose; Dq: Quasi-threshold dose; N: Extrapolation number; SF₂: Surviving fraction at 2 Gy; SER: Sensitization enhancement ratio (calculated as D₀ control/D₀ surufatinib).

Full Size Table

Citation: Huang A, Cao Y, Li B, Xiao J, Zhan SD, Wang NY, Mei XP, Zhao SZ, Han J, Xiao Y, Wang LF, Ma H. Surufatinib achieves radiosensitivity in cholangiocarcinoma by suppressing GINS4 expression to induce Ca²⁺/cAMP signaling activation. World J Gastroenterol 2026; 32(42): 121690
URL: https://www.wjgnet.com/1007-9327/full/v32/i42/121690.htm
DOI: https://dx.doi.org/10.3748/wjg.121690

Huang A, Cao Y, Li B, Xiao J, Zhan SD, Wang NY, Mei XP, Zhao SZ, Han J, Xiao Y, Wang LF, Ma H. Surufatinib achieves radiosensitivity in cholangiocarcinoma by suppressing GINS4 expression to induce Ca²⁺/cAMP signaling activation. World J Gastroenterol 2026; 32(42): 121690 [DOI: 10.3748/wjg.121690]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.